00:00We've been explaining this since I've become the CEO of Nova Nordisk
00:03that while the company has a bright future and in many fronts actually we're progressing well
00:08on one front people should expect that it goes down before it comes back up
00:14and that was the U.S. pricing
00:16We've talked about headwinds on the U.S. pricing impacting our financial numbers
00:20and of course we did not go into the details of the magnitude of that
00:24with the guidance we are giving that a range
00:27what we're basically saying is that it's been well publicized
00:31that due to the most favored nation in U.S., due to the channel mix
00:35due to just general prices coming down
00:37also in the cash we are creating affordability for the patients
00:41millions of patients that are right now in need of GLP-1 products
00:45but simply could not afford it
00:47to do that short term we have to take a headwind
00:51but of course there's a very long tailwind for years to come
Commenti